View : 61 Download: 0

Topoisomerase II alpha and microtubule-associated protein-tau as a predictive marker in axillary lymph node positive breast cancer

Title
Topoisomerase II alpha and microtubule-associated protein-tau as a predictive marker in axillary lymph node positive breast cancer
Authors
Won, Hye SungLee, Kyoung EunSung, Sun HeeChoi, Moon YoungJo, Jung YounNam, Eun MiMun, Yeung-ChulSeong, Chu-MyongLee, Soon Nam
Ewha Authors
이순남성순희성주명이경은문영철남은미
SCOPUS Author ID
이순남scopus; 성순희scopus; 성주명scopus; 이경은scopus; 문영철scopus; 남은미scopus
Issue Date
2014
Journal Title
TUMORI
ISSN
0300-8916JCR Link2038-2529JCR Link
Citation
vol. 100, no. 1, pp. 80 - 86
Keywords
breast cancertopoisomerase II alphamicrotubule-associated protein-tauanthracyclinetaxane
Publisher
PENSIERO SCIENTIFICO EDITOR
Indexed
SCI; SCIE; SCOPUS WOS scopus
Abstract
Aims and background. The aims of this study were to investigate the correlation between topoisomerase II alpha (TOP2A), microtubule-associated protein-tau (MAP-tau) and other prognostic factors in breast cancer and to evaluate the predictive value of TOP2A and MAP-tau in breast cancer patients who received anthracycline and taxane-containing adjuvant chemotherapy. Methods and study design. Seventy patients with axillary lymph node positive breast cancer who underwent curative surgery between January 2000 and December 2005 were evaluated retrospectively. The levels of protein expression of TOP2A and MAP-tau were assessed using immunohistochemistry. Results. Among the 70 patients, 43 (61.4%) showed TOP2A overexpression and 30 (42.9%) showed MAP-tau positivity. TOP2A overexpression was associated with p53 positivity and high histological grade. MAP-tau positivity was associated with a lower positive lymph node ratio, lower proliferative activity, and hormone receptor positivity. Based on the TOP2A and MAP-tau expression, there was no significant difference in disease-free survival in the breast cancer patients who received anthracycline and taxane-containing adjuvant chemotherapy. Conclusions. We conclude that immunohistochemical analysis of TOP2A and MAP-tau protein expression may not predict the benefits of adjuvant anthracycline and taxane chemotherapy in axillary node positive breast cancer.
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE